Diacarta isn't chasing the crowded gene therapy hype—they're building precision tools for rare genetic diseases. With $53M in funding and a laser focus on VEXAS syndrome, this 70-person outfit is betting big on niche diagnostics.

"Diacarta isn't building a platform—they're building a precision weapon for a disease most biotechs ignore."

Their tech stack reveals a pragmatic approach: jQuery and Bootstrap (not cutting-edge, but stable), Chart.js for data visualization, and Ant Design for internal tools. This isn't a startup obsessed with flashy frontend—they're spending engineering hours on molecular biology, not React components. The 40% direct traffic is telling: when clinicians need Diacarta, they go straight to the source. No SEO games, just pure brand recall from medical conferences and peer recommendations.

• VEXAS syndrome is their Trojan horse—2,670 monthly searches with zero competition
• $53M funding on $5.4M revenue = 9.8x burn ratio (classic pre-revenue biotech)
• 70 employees = lean clinical team, not bloated corporate structure
• 40% direct traffic = strong word-of-mouth in medical community
• Their keywords reveal a clinical focus: 'NGS panels' and 'qPCR primers' are lab tools, not consumer products